168 related articles for article (PubMed ID: 9373795)
1. Effect of granulocyte-macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemo-radiotherapy.
Rosso M; Blasi G; Gherlone E; Rosso R
J Chemother; 1997 Oct; 9(5):382-5. PubMed ID: 9373795
[TBL] [Abstract][Full Text] [Related]
2. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.
Chi KH; Chen CH; Chan WK; Chow KC; Chen SY; Yen SH; Chao JY; Chang CY; Chen KY
J Clin Oncol; 1995 Oct; 13(10):2620-8. PubMed ID: 7595716
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Lusso MR; Camboni P; Ferreli L; Mocci M; Perboni S; Mura L; Madeddu C; Macciò A
Oncol Rep; 2003; 10(1):197-206. PubMed ID: 12469169
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma.
Kannan V; Bapsy PP; Anantha N; Doval DC; Vaithianathan H; Banumathy G; Reddy KB; Kumaraswamy SV; Shenoy AM
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1005-10. PubMed ID: 9169806
[TBL] [Abstract][Full Text] [Related]
5. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
Ryu JK; Swann S; LeVeque F; Scarantino CW; Johnson D; Chen A; Fortin A; Pollock J; Kim H; Ang KK
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):643-50. PubMed ID: 17293228
[TBL] [Abstract][Full Text] [Related]
6. Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis.
Sprinzl GM; Galvan O; de Vries A; Ulmer H; Gunkel AR; Lukas P; Thumfart WF
Eur J Cancer; 2001 Nov; 37(16):2003-9. PubMed ID: 11597377
[TBL] [Abstract][Full Text] [Related]
7. The optimal use of granulocyte macrophage colony stimulating factor in radiation induced mucositis in head and neck squamous cell carcinoma.
Patni N; Patni S; Bapna A
J Cancer Res Ther; 2005; 1(3):136-41. PubMed ID: 17998644
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature.
Rossi A; Rosati G; Colarusso D; Manzione L
Oncology; 2003; 64(4):353-60. PubMed ID: 12759532
[TBL] [Abstract][Full Text] [Related]
9. Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study.
Saarilahti K; Kajanti M; Joensuu T; Kouri M; Joensuu H
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):479-85. PubMed ID: 12243825
[TBL] [Abstract][Full Text] [Related]
10. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation.
Gordon B; Spadinger A; Hodges E; Ruby E; Stanley R; Coccia P
J Clin Oncol; 1994 Sep; 12(9):1917-22. PubMed ID: 7916041
[TBL] [Abstract][Full Text] [Related]
11. Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash.
Nicolatou-Galitis O; Dardoufas K; Markoulatos P; Sotiropoulou-Lontou A; Kyprianou K; Kolitsi G; Pissakas G; Skarleas C; Kouloulias V; Papanicolaou V; Legakis NJ; Velegraki A
J Oral Pathol Med; 2001 Sep; 30(8):471-80. PubMed ID: 11545238
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of the effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients during X-radiation therapy: a preliminary report.
Nicolatou O; Sotiropoulou-Lontou A; Skarlatos J; Kyprianou K; Kolitsi G; Dardoufas K
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):551-6. PubMed ID: 9806514
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study.
Makkonen TA; Minn H; Jekunen A; Vilja P; Tuominen J; Joensuu H
Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):525-34. PubMed ID: 10701730
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
15. Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes.
Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Ferreli L; Camboni P; Lusso MR; Mocci M; Madeddu C; Mura L; Mudu MC; Proto E; Tore G; Mura M; Macciò A; Ferreli A; Amichetti M
Oncol Rep; 2003; 10(3):759-66. PubMed ID: 12684655
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer.
McAleese JJ; Bishop KM; A'Hern R; Henk JM
Br J Radiol; 2006 Jul; 79(943):608-13. PubMed ID: 16823067
[TBL] [Abstract][Full Text] [Related]
17. Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.
Stokman MA; Spijkervet FK; Boezen HM; Schouten JP; Roodenburg JL; de Vries EG
J Dent Res; 2006 Aug; 85(8):690-700. PubMed ID: 16861284
[TBL] [Abstract][Full Text] [Related]
18. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
19. Concomitant administration of two standard regimens of chemotherapy and radiotherapy in advanced squamous carcinoma of the head and neck: a feasibility study.
Benasso M; Corvò R; Numico G; Cavallari M; Blengio F; Sanguineti G; Rosso M; Merlano M
Anticancer Res; 1995; 15(6B):2651-4. PubMed ID: 8669841
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
